How a UK Startup Is Using AR to Reinvent Neurorehabilitation Funding

Jan de Vries · 2026-09-03

When you think about recovery from a stroke or a serious neurological condition, augmented reality probably isn't the first thing that comes to mind. But for Strolll, a Stafford-based medtech company, AR glasses are becoming a game-changer in how patients regain movement and independence. The company just landed a significant financial boost to accelerate its mission, and the details are worth a closer look. ### A Fresh Injection of Capital Strolll, which builds software-as-a-medical-device (SaMD) solutions, has raised a new round of investment led by IW Capital, with participation from heavy hitters like the Cleveland Clinic and Future Planet Capital Regional. That's not all. Innovate UK, the UK's innovation agency, has separately awarded the company a $4.86 million innovation loan and a $946,000 Growth Catalyst Investor Partnerships (GCIP) award. Combined, these two grants total about $5.8 million for two distinct projects. This news comes on the heels of a $14.2 million Series A round in March 2025, also led by IW Capital. So what's the big picture here? Strolll is clearly positioning itself as a leader in the neurorehabilitation space, and investors are paying attention. ### Why This Funding Matters Jorgen Ellis, CEO and co-founder of Strolll, put it simply: "Our team is committed to revolutionising rehabilitation for those living with neurological disorders." The funding will help the company increase patient engagement, support recovery progression, and help clinicians deliver effective neurorehabilitation to a wider patient population. Founded in 2018, Strolll develops digital therapeutics delivered through AR glasses. The technology provides clinically proven and patented neurorehabilitation for patients with neurological disorders, supporting therapy both in clinics and at home. The neurorehabilitation market is growing, driven by an aging population and increased survival rates from acute neurological events. Strolll's approach makes rehab more engaging and accessible, which is crucial for long-term recovery. ### Two Big Bets: StrolllAssessment and StrolllAcute The new funding is split between two major initiatives: - **StrolllAssessment:** This platform combines AI with a fully equipped biomechanics lab that mirrors real-world rehab settings. The goal is to compress what traditionally takes years of clinical validation into just months. By running multiple validation studies simultaneously, the platform offers a scalable, standards-compliant way to validate automated clinical assessments. - **StrolllAcute:** This is a bedside-first AR rehab system designed for acute, bed-bound patients. It allows early therapeutic intervention without disrupting existing ward workflows or adding to staff burden. Early mobility in acute care is critical, and this system aims to make it possible without extra strain on nurses and therapists. Scott O'Brien, Chief Investment Officer at Innovate UK, highlighted why Strolll stood out: "Across two innovations, Strolll has secured Innovate UK backing because it has proven both its technical excellence and a credible route to commercial success." He noted that combining debt finance with grants alongside private capital shows a commitment to accelerating innovation and fueling business growth. ### The Bottom Line This investment gives Strolll the runway to extend its product leadership and continue its growth trajectory. For anyone watching the medtech space, this is a clear signal that AR and AI are moving from novelty to necessity in healthcare. The ability to deliver consistent, engaging rehab outside of traditional hospital settings could reshape how neurological care is delivered for years to come. If you're curious about where digital health is heading, Strolll is a name worth keeping on your radar. The blend of cutting-edge technology with practical clinical needs is exactly what the industry needs right now.